Independent preparation notes · issue 01

Preparing For Ibogaine Treatment: A Full Checklist

A practical, evidence-first route through health review, travel logistics, mental readiness, monitoring, and recovery planning—without treating a high-risk intervention like a wellness trip.

Medical first Monitoring matters Recovery is planned early

Read the safety label before the story

Ibogaine is a psychoactive alkaloid associated with Tabernanthe iboga. It is being investigated in relation to substance use disorder and opioid withdrawal, but it carries serious cardiac risks and should never be approached as casual psychedelic therapy.

Any ibogaine treatment discussion starts with physician-led medical screening, medication review, laboratory testing, emergency planning, and continuous cardiac monitoring. The risk-focused overview from ICEERS is useful for keeping public interest separate from clinical suitability.

Preparation should also account for the fact that ibogaine and its metabolite noribogaine can interact with multiple neurochemical systems. The general pharmacology of ibogaine’s documented history and chemistry does not replace individualized medical assessment.

“The first checklist item is not travel. It is whether a qualified clinician says the risk can be managed at all.”

Cut-out #1

Essential medical screening and diagnostic tests

Do not treat a screening packet as administrative paperwork. Medical screening determines whether ibogaine treatment should proceed, pause, or be ruled out.

Cardiac evaluation and ECG requirements

A resting 12-lead electrocardiogram, or ECG, is strictly required. The baseline QTc interval should be below 450 milliseconds for men and 460 milliseconds for women before ibogaine is considered. A clinician must interpret every ECG in the context of symptoms, history, drugs, and family cardiac history.

Ibogaine blocks hERG channels—potassium channels involved in cardiac repolarization. That can delay myocardial repolarization and raise the risk of torsades de pointes, dangerous arrhythmia, bradycardia, cardiac arrest, and sudden deterioration.

Metabolic panel and liver function assessment

A comprehensive metabolic panel, liver function tests, renal function review, and a complete blood count help identify risk before ibogaine therapy. Serum electrolyte levels must show adequate potassium and magnesium because hypokalemia and hypomagnesemia materially elevate drug-induced arrhythmia risk.

Liver function tests and hepatic function matter because metabolism of ibogaine produces long-lived noribogaine. A clinic should explain how the comprehensive metabolic panel is reviewed, whether electrolyte levels are rechecked, and how potassium and magnesium are corrected before any clinical protocol moves forward.

Psychiatric evaluation and absolute contraindications

Psychiatric screening must establish baseline stability, medication history, trauma triggers, and capacity for informed consent. Ibogaine is strictly contraindicated for a personal or first-degree family history of schizophrenia, psychosis, or bipolar I disorder because it may induce prolonged psychotic episodes.

A psychiatric evaluation also identifies whether antidepressants, SSRIs, mood medications, or unresolved acute distress create contraindications. Ibogaine therapy is not an appropriate shortcut around psychiatric screening, mental readiness, or ongoing care.

Records to bring to review

Gather current and recent ECG reports, the complete blood count, comprehensive metabolic panel, liver function tests, medication lists, prior diagnoses, allergy information, and records of hospitalizations. The clinical preparation guidance can help frame the questions a person brings to a treating team.

Keep the medical screening process current. A historical electrocardiogram does not prove that today’s QTc interval, electrolyte levels, blood pressure, or cardiac risk is acceptable.

Cut-out #2

Substance and medication tapering protocol

Washout decisions require clinicians who understand withdrawal, interaction risk, and the actual substances involved. Do not self-direct a tapering schedule.

Opioid transition guidelines for short-acting formulations

Patients using long-acting opioids such as methadone or buprenorphine may need to transition to short-acting opioids for three to six weeks before ibogaine, because long elimination half-lives and displacement risks complicate ibogaine treatment. That transition must be medically supervised.

Methadone, Suboxone, and buprenorphine can each require different planning. A clinician should define the tapering schedule, monitor opioid withdrawal, and determine whether medical detox is needed rather than assuming all long-acting opioids follow one rule.

Medication washout is not optional

SSRIs, MAO inhibitors, other antidepressants, and serotonergic medications require individualized review. A full pharmacological washout is often discussed in the range of two to four weeks to reduce serotonin syndrome risk, but exact timing depends on the medication, dose, hepatic function, and prescribing clinician.

Never stop antidepressants or SSRIs abruptly to meet a retreat date. A medically directed tapering schedule protects against destabilization, discontinuation effects, and avoidable psychiatric risk.

Alcohol, benzodiazepines, and fentanyl

Active alcohol or benzodiazepine dependence can create life-threatening withdrawal seizure risks. Those conditions must be medically stabilized through medical detox before ibogaine therapy is considered. Fentanyl and illicit fentanyl analogues can linger unpredictably in adipose tissue and complicate clinical stabilization.

A truthful substance history gives medical staff the information needed to assess opioid withdrawal, medication interactions, blood pressure changes, and cardiac monitoring needs. Concealed use can turn a fragile clinical protocol into an emergency.

A word on withdrawal expectations

Ibogaine treatment is frequently discussed in connection with opioid withdrawal, but it is not established routine care. The plain-language treatment overview is a reminder to ask what observation, withdrawal care, and recovery support actually exist after dosing.

Medical detox, not a calendar promise, should determine when someone is stable enough for reassessment. A reported cessation date alone cannot demonstrate safety for ibogaine.

Cut-out #3

Physical preparation and nutritional optimization

Physical preparation is simple in principle: stabilize what can be stabilized, report what cannot, and leave decisions about medical suitability to qualified care.

Build stability, not bravado

Hydration, nutritional support, adequate sleep, and an accurate record of vital signs support safer assessment. Blood pressure, pulse, electrolyte levels, potassium, magnesium, and new symptoms should be reviewed rather than minimized.

Talk through any fainting, palpitations, chest pain, breathlessness, seizure history, liver disease, kidney disease, or prior arrhythmia. These details can reveal contraindications to ibogaine treatment before a flood dose is scheduled.

Non-negotiable

Do not use supplements, fasting, exercise, or “clean eating” as a workaround for a concerning ECG, QTc interval, poor hepatic function, unstable blood pressure, or abnormal electrolyte levels.

Cardiac arrest and arrhythmia are safety concerns that require medical judgment and emergency capability—not personal optimization.

Cut-out #4

Psychological readiness and intention setting

Mental readiness is not a guarantee of a good outcome. It is a way to identify support needs before a difficult acute experience and a vulnerable recovery period.

Pre-treatment intention setting, paired with somatic grounding techniques, can help a person navigate the acute dream-like or oneiric state without panic-driven tachycardia. Intention setting is not about forcing an outcome; it is about naming what requires care, support, and follow-through.

Psychiatric screening should identify traumatic triggers that may surface during the acute visionary phase. Those with a history of psychosis, schizophrenia, or bipolar disorder need a careful exclusion process rather than reassurance from a nonmedical source.

The discussion of spiritual preparation may be meaningful to some people, but spiritual framing cannot substitute for psychiatric screening, cardiac monitoring, or a documented clinical protocol.

For an independent explanation of this project’s scope, see how Prebogaine Preparation frames its independent resource. The aim is clarity about questions to bring to clinicians, not an endorsement of a provider or a promise about ibogaine therapy.

Cut-out #5

How to vet an ibogaine clinic and safety standards

Location, atmosphere, and testimonials do not establish safety. Ask operational questions and seek answers that can be verified.

Staff and emergency readiness

High-standard ibogaine centers should use board-certified physicians, maintain ACLS certified medical staff on-site 24/7, and keep emergency medical equipment—including an automated external defibrillator—in the dosing room. Ask who monitors vital signs and who responds if a QTc interval changes.

Continuous cardiac telemetry monitoring is widely treated as the international safety standard through the 24- to 36-hour acute visionary and recovery phase. Cardiac monitoring should not end when a flood dose feels “complete.”

Transfer agreements and access to care

Ask about proximity to an intensive care hospital unit, written transport agreements, emergency medical equipment, and a verifiable safety record. A defibrillator is not the whole emergency plan; trained medical staff, rapid escalation, and clear safety protocols all matter.

The clinic-oriented preparation checklist is one example of questions to compare against a provider’s own clinical protocol.

Travel is part of the risk plan

Mexico and Costa Rica are frequently discussed destinations, but travel arrangements should follow medical clearance, not precede it. Plan for a support person when appropriate, flexible return dates, accessible records, and a recovery buffer instead of immediate obligations after ibogaine treatment.

People comparing overseas options can use the location-oriented treatment directory discussion only as a starting point for questions, not as proof of clinic accreditation or safety.

Ask about the actual protocol

Ask whether medical screening is repeated on arrival, how the ECG and electrocardiogram are interpreted, how electrolyte levels are managed, when cardiac monitoring begins and ends, and what circumstances cancel or delay treatment. The expectations overview can help a person articulate logistics questions before travel.

Clinic accreditation standards differ by jurisdiction. The important point is to verify what oversight, emergency access, staffing, and safety protocols actually apply where care is offered.

Mixtape proof list

Packing checklist for your ibogaine retreat

Pack for medical handoff and gentle recovery, not for a curated experience. Confirm what a facility permits before departure.

Medical documents

Current medication and supplement list, including antidepressants and SSRIs
Recent ECG or electrocardiogram results and clinician notes
Complete blood count, comprehensive metabolic panel, liver function tests, and renal function records
Allergy details, diagnoses, emergency contacts, and insurance or travel documentation

Comfort and recovery basics

Comfort items approved by the facility, such as soft layers and familiar toiletries
A packing list for hydration supplies and any clinician-approved nutritional support
Loose clothing for monitoring access and a calm travel day
Written contacts for an integration coach, therapist, and peer support network

Before you zip the bag

Review the admissions-style packing prompts alongside the facility’s instructions. Do not carry unreported medication, substances, or supplements into a medical setting.

Comfort items can help with recovery, but they do not replace hydration assessment, vital signs, cardiac monitoring, or care from medical staff.

Keep plans flexible

Travel arrangements should leave room for additional observation, delayed flights, and a quiet transition home. The travel-and-preparation perspective may help people list logistics, while the final plan should remain tied to clinician instructions.

Do not schedule demanding work, caregiving, legal meetings, or long solo travel immediately after a flood dose. Recovery needs protected time.

After the loud part

Post-treatment integration and aftercare planning

Integration begins before arrival. The most durable preparation is a concrete aftercare plan with dates, people, and realistic support.

Noribogaine is a long-lived metabolite of ibogaine. It is associated with a post-dose neurochemical window sometimes discussed alongside neuroplasticity and BDNF, or brain-derived neurotrophic factor. The biological language should not overstate certainty: ibogaine therapy is not a complete treatment system for substance use disorder.

A concrete aftercare plan can include scheduled psychotherapy, holistic support such as clinician-approved bodywork, an integration coach, and peer support. Arrange these contacts before travel so integration has structure when the acute afterglow fades and recovery becomes ordinary life again.

For a broader evidence context, the ClinicalTrials.gov study registry shows why medically supervised research protocols use defined monitoring and follow-up rather than treating a single experience as sufficient care.

Prebogaine Preparation’s topic-guidance pages are designed to help readers organize safety questions, records, and preparation notes. They do not replace an integration coach, medical staff, psychotherapy, or clinical decision-making.

Field notes

Questions to ask before committing

What medical tests are mandatory before undergoing ibogaine treatment?

At minimum, expect medical screening that includes a resting 12-lead ECG, QTc interval review, electrolyte levels, potassium and magnesium assessment, comprehensive metabolic panel, liver function tests, renal function review, complete blood count, medication review, and psychiatric screening. Individual clinicians may require more testing based on history.

How long before treatment must patients taper off psychiatric drugs and opioids?

Long-acting opioids such as methadone, Suboxone, and buprenorphine are commonly discussed as requiring a transition to short-acting opioids for three to six weeks. SSRIs and other antidepressants can require a two- to four-week washout. Only a prescribing clinician and medical team can set a tapering schedule or determine medical detox needs.

What are the most critical cardiac risks and physical contraindications associated with ibogaine?

QTc interval prolongation, bradycardia, torsades de pointes, arrhythmia, and cardiac arrest are core concerns. hERG channels, electrolyte levels, potassium, magnesium, hepatic function, medication interactions, and a person’s cardiac history all affect risk. Continuous cardiac monitoring and emergency medical equipment are central safety protocols.

How should patients mentally and emotionally prepare for an ibogaine experience?

Use psychiatric screening, intention setting, somatic grounding, honest discussion of trauma triggers, and clear support arrangements. The intention-setting prompt shared by Ambio Life Sciences reflects one way providers discuss preparation, but mental readiness never removes medical contraindications.

Why is post-treatment integration planning essential prior to taking a flood dose?

Recovery is vulnerable after the acute phase. An aftercare plan with psychotherapy, an integration coach, peer support, practical housing and work planning, and substance use disorder care gives integration a durable structure. The provider preparation outline can offer additional questions to bring to a medical team.

What should be avoided before an ibogaine retreat?

Do not conceal substances, change prescriptions independently, ignore opioid withdrawal, or proceed with unresolved alcohol or benzodiazepine dependence. The safety-focused list of pre-retreat cautions reinforces why every medication, supplement, and new symptom belongs in medical screening.

Keep this principle close

A checklist is only useful when it leads to safer decisions.

Ask for clear medical screening, an ECG and electrocardiogram review, cardiac monitoring, ACLS certified medical staff, emergency transfer planning, and an aftercare plan before considering ibogaine treatment. If answers are vague, pause.

For further context, see ibogaineantiaddiction.com.